Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence
Breast Cancer Research volume 17, Article number: 87 (2015)
During the editorial process preceding the publication of this article an error was introduced in the heading of “Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients.” This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled “Elafin Negative.” The data-containing column on the right should in fact be labeled “Elafin Positive (n = 482).” The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.
Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, et al. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Canc Res. 2014;16:3417.
The online version of the original article can be found under doi:10.1186/s13058-014-0497-4.
About this article
Cite this article
Caruso, J.A., Karakas, C., Zhang, J. et al. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 17, 87 (2015). https://doi.org/10.1186/s13058-015-0572-5